Theralase Technologies Inc
XTSX:TLT
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
|
Theralase Technologies Inc
XTSX:TLT
|
78.4m CAD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
193.3B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172.1B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
134.8B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
113.8B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
106.2B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.4B EUR |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.7B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
47.3B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
46.4B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
34.1B USD |
Loading...
|
Market Distribution
| Min | -10 058.3% |
| 30th Percentile | 20.4% |
| Median | 33.6% |
| 70th Percentile | 50.5% |
| Max | 717.4% |
Other Profitability Ratios
Theralase Technologies Inc
Glance View
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in East York, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. The firm operates through two divisions, The Anti-Cancer Therapy (ACT) and The Cool Laser Therapy (CLT). ACT division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. CLT division designs, develops, manufactures and markets patented, and its laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerves, muscle and joint conditions. The firm develops products both internally and using the assistance of external resources.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Theralase Technologies Inc is 55.3%, which is above its 3-year median of 53.2%.
Over the last 3 years, Theralase Technologies Inc’s Gross Margin has increased from 47.2% to 55.3%. During this period, it reached a low of 47.2% on Sep 30, 2022 and a high of 55.8% on Jun 30, 2025.
